Share this article and save a life!
Your radiologist just missed nearly half the aneurysms that are growing.
That’s what new data from RapidAI revealed this week.
Their AI platform caught 27 out of 28 cases of aneurysm growth.
Radiologists working alone? Only 14 out of 28.
Let that sink in: **46% more detection** when AI assists.
This isn’t about replacing radiologists. It’s about catching the subtle, linear growth patterns that human eyes struggle to see consistently. The kind that determines whether someone needs preventive surgery or can wait.
Here’s what makes this breakthrough different:
• Maintains the same specificity as human readers (no false alarm fatigue)
• Captures longitudinal changes across multiple scans
• Enables earlier intervention decisions for rupture risk
But the real story goes deeper.
The same AI system also improved stroke diagnosis accuracy from 76% to 86%, while cutting interpretation time by 34 seconds per case. General radiologists saved over a minute per scan.
Think about the downstream impact:
Every missed aneurysm growth is a potential emergency room catastrophe waiting to happen. A ruptured brain aneurysm has a 40% mortality rate. Those who survive often face permanent disability.
Now multiply that by every radiology department still relying solely on human eyes.
The question isn’t whether AI belongs in radiology anymore.
It’s whether we can afford NOT to use it.
Because somewhere right now, a growing aneurysm is being missed. And that patient deserves better than a coin flip chance of detection.
What’s stopping your imaging center from adopting this technology today?
♻️ Repost if AI should be standard in aneurysm monitoring
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
